AKTS

Aktis Oncology Inc

15.06

Oct 16 • 3:59 PM ET -0.95 (-5.93%)

15.12

Aftermarket • 7:30 PM ET +0.06 (0.40%)

Healthcare Biotechnology USA Small NASD

Peers: IDYA RCUS TNGX CGON KYMR BMRN CRNX RYTM INCY KRYS

| Held by: VTI IWM XBI VXF VTWO IWO SCHA IWN YALL ITOT

Scroll to Statements

Index	RUT
Market Cap	837.63M
Enterprise Value	331.55M
Income	-
Sales	-
Book/sh	8.76
Cash/sh	9.30
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	79
IPO	Jan 09, 2026

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	1.72
P/C	1.62
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	16.33
Current Ratio	16.33
Debt/Eq	0.02
LT Debt/Eq	0.02
Option/Short	Yes / Yes

EPS (ttm)	-
EPS next Y	-2.25
EPS next Q	-0.46
EPS this Y	97.72%
EPS next Y	-26.15%
EPS next 5Y	68.48%
EPS past 3/5Y	-47.94% -
Sales past 3/5Y	- -
EPS Y/Y TTM	-
Sales Y/Y TTM	-
EPS Q/Q	-55.52%
Sales Q/Q	133.86%
Earnings	Aug 13 AMC
EPS/Sales Surpr.	-0.19% 25.44%

Insider Own	43.37%
Insider Trans	-0.50%
Inst Own	43.73%
Inst Trans	-0.82%
ROA	-
ROE	-
ROIC	-
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-18.52%
SMA50	-32.24%
SMA200	-29.21%
Trades

Shs Outstand	53.45M
Shs Float	31.50M
Short Float	14.97%
Short Ratio	13.14
Short Interest	4.72M
52W High	34.19 -55.95%
52W Low	14.72 2.31%
Volatility	7.08% 5.63%
ATR (14)	1.11
RSI (14)	18.26
Beta	-
Rel Volume	1.10
Avg Volume	358.91K
Volume	394,795

Perf Week	-17.02%
Perf Month	-34.12%
Perf Quarter	-37.15%
Perf Half Y	-25.63%
Perf YTD	-44.22%
Perf Year	-
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	1.00
Target Price	35.41
Prev Close	16.01
Price	15.06
Change %	-5.93%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-09-26	Initiated	Oppenheimer	Outperform	$40
Aug-19-26	Initiated	Wedbush	Outperform	$35
Aug-19-26	Initiated	BMO Capital Markets	Outperform	$37
Jun-16-26	Initiated	Raymond James	Strong Buy	$40
Apr-29-26	Initiated	William Blair	Outperform
Mar-09-26	Initiated	H.C. Wainwright	Buy	$30
Feb-03-26	Initiated	TD Cowen	Buy
Feb-03-26	Initiated	Leerink Partners	Outperform	$31
Feb-03-26	Initiated	JP Morgan	Overweight	$30
Feb-03-26	Initiated	BofA Securities	Buy	$34

Oct-01-26 08:00AM	Aktis Oncology Initiates Second Phase 1b Clinical Trial for AKY-2519, a Miniprotein Radioconjugate Targeting B7-H3 (GlobeNewswire)
Sep-09-26 08:00AM	Aktis Oncology to Present at Upcoming September Investor Conferences (GlobeNewswire)
Aug-13-26 04:19PM	Aktis: Q2 Earnings Snapshot (Associated Press)
04:01PM	Aktis Oncology Reports Financial Results and Business Highlights for the Second Quarter 2026 (GlobeNewswire)
May-27-26 04:05PM	Aktis Oncology to Present at the Jefferies Global Healthcare Conference (GlobeNewswire)
05:21PM	Loading…
May-21-26 05:21PM	Aktis Oncology Reports First-in-Human Clinical Imaging and Dosimetry Data for AKY-2519 Demonstrating Robust Tumor Uptake and Limited Normal Tissue Exposures in Patients with B7-H3 Expressing Tumors (GlobeNewswire) +6.38%
May-11-26 04:56PM	Aktis: Q1 Earnings Snapshot (Associated Press) +7.99%
04:01PM	Aktis Oncology Reports Financial Results and Business Highlights for First Quarter 2026 (GlobeNewswire)
May-06-26 08:00AM	Aktis Oncology to Present at the BofA Securities Health Care Conference (GlobeNewswire)
May-04-26 04:05PM	Aktis Oncology Initiates Phase 1b Clinical Trial for AKY-2519, a B7-H3 Miniprotein Radioconjugate, in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (GlobeNewswire)
Apr-21-26 05:00PM	Aktis Oncology Announces Presentation of First Clinical Imaging and Dosimetry Data for AKY-2519 at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire) +7.32%
Apr-16-26 08:00AM	Aktis Oncology Appoints Industry Research and Development Veteran Glenn Gormley, MD, PhD to its Board of Directors (GlobeNewswire)
Mar-30-26 04:01PM	Aktis Oncology Announces FDA Clearance of Investigational New Drug Applications for AKY-2519 and Provides Business Updates and Full Year 2025 Financial Results (GlobeNewswire) +8.89% +8.16%
Mar-03-26 08:02PM	Aktis Oncology Details Radiopharma Expansion, Fast Track Win for AKY-1189 at TD Cowen Conference (MarketBeat)
Feb-24-26 04:05PM	Aktis Oncology to Present at Upcoming March Investor Conferences (GlobeNewswire)
12:02PM	Loading…
12:02PM	Medtronic Diabetes Unit MiniMed Seeks $784 Million in US IPO (Bloomberg)
08:00AM	Aktis Oncology Receives U.S. FDA Fast Track Designation for AKY-1189, a Nectin-4 Miniprotein Radioconjugate (GlobeNewswire)
Feb-05-26 01:21PM	Merck veteran Perlmutter-led Eikon Therapeutics valued at $860 million in Nasdaq debut (Reuters)
Feb-03-26 09:34AM	Adobe downgraded, Palantir upgraded: Wall Street's top analyst calls (The Fly)
Jan-27-26 11:39AM	Should You Buy PICS Stock After the PicPay IPO? (Barchart)
Jan-19-26 08:45AM	Huge Insider Buying Now at This Insurance Giant and 2 Biotechs (24/7 Wall St.)
Jan-17-26 07:00AM	MarketBeat Week in Review 01/12 - 01/16 (MarketBeat)
Jan-14-26 09:31AM	A Fresh IPO That Long-Term Investors Shouldn't Ignore (MarketBeat)
Jan-13-26 06:30AM	Aktis Oncology Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Jan-09-26 12:58PM	Vida Ventures Congratulates Aktis Oncology on Its Entry into the Public Markets (Business Wire)

Aktis Oncology, Inc. is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The company was founded by Todd Foley, Patrick Baeuerle and Brian Goodman in August 2020 and is headquartered in Boston, MA.

Co-Founder & ChairmanMr. Todd Foley M.B.A.

PresidentDr. Matthew Roden Ph.D.

Chief Scientific OfficerDr. Paul L. Feldman Ph.D.

Ph.D.Dr. Akos Czibere M.D.

Co-Founder & Member of Scientific Advisory BoardDr. Patrick A. Baeuerle Ph.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Czibere Akos	Chief Medical Officer	Sep 23 '26	Option Exercise	4.95	12,500	61,875	12,500	Sep 24 04:05 PM
Czibere Akos	Chief Medical Officer	Sep 23 '26	Sale	20.69	12,500	258,621	0	Sep 24 04:05 PM
Akos Czibere	Officer	Sep 23 '26	Proposed Sale	22.11	25,000	552,750		Sep 23 04:20 PM
Herrmann Ken	Director	Jul 20 '26	Option Exercise	0.59	4,856	2,859	4,856	Jul 21 08:50 PM
Herrmann Ken	Director	Jul 20 '26	Sale	24.56	4,856	119,274	0	Jul 21 08:50 PM
Herrmann Ken	Director	Jul 17 '26	Option Exercise	0.08	3,065	245	3,065	Jul 20 05:34 PM
Herrmann Ken	Director	Jul 17 '26	Sale	25.21	3,065	77,259	0	Jul 20 05:34 PM
KEN HERRMANN	Director	Jul 20 '26	Proposed Sale	24.56	4,856	119,275		Jul 20 04:51 PM
KEN HERRMANN	Director	Jul 17 '26	Proposed Sale	25.21	3,065	77,259		Jul 17 05:26 PM
Ron-Bigger Shulamit	Chief Operating Officer	Jul 08 '26	Option Exercise	3.66	50,000	183,000	50,000	Jul 10 06:11 AM
Ron-Bigger Shulamit	Chief Operating Officer	Jul 08 '26	Sale	27.75	50,000	1,387,558	0	Jul 10 06:11 AM
Czibere Akos	Chief Medical Officer	Jul 08 '26	Option Exercise	4.95	50,000	247,500	50,000	Jul 10 06:10 AM
Czibere Akos	Chief Medical Officer	Jul 08 '26	Sale	27.77	50,000	1,388,701	0	Jul 10 06:10 AM
AKOS CZIBERE	Officer	Jul 08 '26	Proposed Sale	27.77	50,000	1,388,700		Jul 08 04:28 PM
SHULAMIT RON-BIGGER	Officer	Jul 08 '26	Proposed Sale	27.75	50,000	1,387,560		Jul 08 04:22 PM
Foley Todd	Director	Jan 12 '26	Buy	18.00	232,870	4,191,660	4,235,403	Jan 14 06:20 PM
MPM BIOVENTURES 2018, L.P.	10% Owner	Jan 12 '26	Buy	18.00	1,112,777	20,029,986	10,260,064	Jan 14 06:19 PM
GADICKE ANSBERT	10% Owner	Jan 12 '26	Buy	18.00	1,112,777	20,029,986	10,260,064	Jan 14 06:17 PM
EcoR1 Capital, LLC	Director	Jan 12 '26	Buy	18.00	2,222,222	39,999,996	4,348,658	Jan 12 08:28 PM
Vida Ventures II, LLC	10% Owner	Jan 12 '26	Buy	18.00	835,000	15,030,000	5,671,825	Jan 12 05:10 PM
Kim Helen Susan	Director	Jan 12 '26	Buy	18.00	835,000	15,030,000	5,671,825	Jan 12 05:00 PM

AKTS

Aktis Oncology Inc

Upgrade your Finviz experience